Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis

Gene Expression Differences between Psoriasis Patients with and without Inflammatory Arthritis

(2015) Remy A. Pollock et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice

(2015) L. Spelman et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Systemically Elevated Th1-, Th2- and Th17-associated Chemokines in Psoriasis Vulgaris Before and After Ultraviolet B Treatment

(2014) A Ekman et al.   ACTA DERMATO-VENEREOLOGICA

Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases

(2013) Alessandro Antonelli et al.   AUTOIMMUNITY REVIEWS

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics

(2013) Philip J. Mease et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?

(2011) D. D. Gladman et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

(2011) Michael Yellin et al.   ARTHRITIS AND RHEUMATISM

Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-γ dysregulation

(2008) Judith A. Smith et al.   ARTHRITIS AND RHEUMATISM

CXCL10 and autoimmune diseases

(2008) Eun Young Lee et al.   AUTOIMMUNITY REVIEWS